MYELOFIBROSIS

This study directly compares two already-approved drugs, momelotinib and ruxolitinib, for people newly diagnosed with myelofibrosis who also have low blood cell counts. The main goal is to see which drug is better at shrinking an enlarged spleen and reducing the need for blood tr…

This study is testing whether a combination of two drugs, pacritinib and selinexor, can help control myelofibrosis in patients who have not yet tried a common type of treatment (JAK inhibitors) and who have low red blood cell and platelet counts. The main goals are to see if the …

This early-stage study is testing a new drug called rebecsinib in patients with two types of advanced blood cancers: secondary acute myeloid leukemia that has returned or not responded to treatment, and higher-risk myelofibrosis. The main goals are to find the safest dose and see…

This study is testing whether adding a new drug called bomedemstat to an existing drug (momelotinib) can better control myelofibrosis, a serious bone marrow disease. It is for patients who have not had an optimal response to momelotinib alone. About 40 participants will take mome…

This early-stage study is testing an experimental oral medication called PMD-026 for people with myelofibrosis, a serious bone marrow cancer. The trial will first find the safest dose and then check if the drug can reduce spleen size and ease symptoms like fatigue and pain. It's …

This study is creating a national registry to track how 200 patients with myelofibrosis (a rare bone marrow cancer) and anemia are treated in real-world German clinics. It will follow patients for up to three years to document which treatment sequences doctors use, how patients r…

This early study aims to understand how a single dose of the experimental drug TQ05105 is processed by the body in people with mild or moderate liver problems, compared to healthy people. It will involve 24 adults to measure drug levels in the blood and check for safety. The goal…